252 results
Page 6 of 13
424B5
uyi0mb
1 Aug 19
Prospectus supplement for primary offering
5:19pm
424B5
7c9wtb0q15hruh1q6a
31 Jul 19
Prospectus supplement for primary offering
4:38pm
8-K
EX-99.4
hfempnz
26 Jul 19
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
EX-99.3
mve5xfhm92 d22dh4b
26 Jul 19
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
EX-99.1
vpfqw8zbcms 0b
21 May 19
Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
4:06pm
8-K
EX-99.1
hoyprwthpfvpos
9 May 19
Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
4:34pm
8-K
EX-99.1
lw58b 7m7zu63
18 Jan 19
Adamis’ Commercial Partner Launches SYMJEPITM(epinephrine) in the US
5:01pm
8-K
EX-99.1
io5pe8b
7 Dec 18
Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI
4:17pm
8-K
EX-99.1
q7gkfic
14 Nov 18
Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update
4:28pm
8-K
EX-99.1
r0p quydwiczco1
28 Sep 18
Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
9:03am
8-K
EX-99.1
og93kkqfgqjjhie
10 Aug 18
Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
4:15pm
424B5
8gtw0qi xufnyki4ab6x
2 Aug 18
Prospectus supplement for primary offering
9:17pm
424B5
hexewe6crv4u
1 Aug 18
Prospectus supplement for primary offering
4:16pm
8-K
wtz3npr iinafzobg
2 Jul 18
Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi
1:16pm